AVR
$5.97
Anteris Technologies Global Corp., a structural heart company, develops and commercializes minimally invasive medical devices to treat heart valve diseases.
Historical Price
Peer Comparison
Whystock Valuation Model
Fundamentals
Anteris Technologies Global Corp., a structural heart company, develops and commercializes minimally invasive medical devices to treat heart valve diseases. It offers the DurAVR transcatheter heart valve system, a novel transcatheter aortic valve for...
Recent News
Anteris Technologies Global CEO Touts DurAVR Redesign, Durability Claims and TAVR Market Strategy
Anteris Technologies Global (NASDAQ:AVR) CEO and founder Wayne Paterson discussed the company’s DurAVR transcatheter aortic valve replacement (TAVR) program, recent clinical visibility, and the company’s approach to market development during a conversation that touched on product design, tissue scie
Anteris Technologies Global Highlights DurAVR TAVR Data, PARADIGM Pivotal Trial Plans at TD Cowen Conference
Anteris Technologies Global (NASDAQ:AVR) Chief Executive Officer Wayne Paterson outlined the company’s DurAVR transcatheter aortic valve replacement (TAVR) program during a fireside chat at TD Cowen’s conference in Boston, focusing on the platform’s design rationale, early clinical experience, and t
Anteris reports US$77.8m 2025 net operating cash outflow as PARADIGM trial gets underway
Anteris Technologies Pty Ltd (ASX:AVR, NASDAQ:AVR) has reported a net operating cash outflow of US$77.8 million for the year ended December 31, 2025, as it increased spending across clinical, regulatory and manufacturing work to support its global pivotal PARADIGM trial. The structural heart...
Anteris Technologies price target lowered to $15 from $20 at Lake Street
Lake Street analyst Frank Takkinen lowered the firm’s price target on Anteris Technologies (AVR) to $15 from $20 and keeps a Buy rating on the shares. $320M in gross financing, which included a $90M strategic investment from Medtronic (MDT), was “a transformational deal for Anteris,” says the analyst, who reduced the firm’s target on the dilutive impact of the financing. However, the financing “relieves the capital overhang, verifies the product’s viability, and entrenches Medtronic as a collabo
Retail investors who hold 25% of Anteris Technologies Global Corp. (ASX:AVR) gained 41%, institutions profited as well
Key Insights The considerable ownership by retail investors in Anteris Technologies Global indicates that they...